Common Ground Among Companies Developing Diabetes Treatments

Video

There is significant competition among companies developing treatments for diabetes. In spite of that, the common goal for all treatments is to help the growing number of patients developing the condition to better control their symptoms and overall health.

%jwplayer%

There is significant competition among companies developing treatments for diabetes. In spite of that, the common goal for all treatments is to help the growing number of patients developing the condition to better control their symptoms and overall health.

As the Vice President of Late Stage Development for Diabetes and Endocrinology at Merck Research Laboratories, Peter P. Stein, MD, said his company is working hard to be among the leaders in the field of diabetes care. Speaking at the annual meeting of the American Diabetes Assocation in New Orleans, Stein said with diabetes presenting different challenges in each patient it is important to have a variety of options available to address the problems patients face on a daily basis.

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
Gestational Low-Dose Aspirin Does Not Increase Risk of IBD Flares in Women
Riha Bhatt, MD: Mimickers and Concurrent Diseases in Pediatric IBD
© 2024 MJH Life Sciences

All rights reserved.